Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 88 articles:
HTML format
Text format



Single Articles


    July 2019
  1. AZAM S, Eriksson M, Sjolander A, Hellgren R, et al
    Mammographic Density Change and Risk of Breast Cancer.
    J Natl Cancer Inst. 2019 Jul 12. pii: 5531652. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2019
  2. SACCARELLI CR, Bitencourt AGV, Morris EA
    Breast cancer screening in high-risk women: is MRI alone enough?
    J Natl Cancer Inst. 2019 Jun 24. pii: 5522375. doi: 10.1093.
    PubMed     Text format    


  3. ROSSI PG, Paci E
    RE: Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
    J Natl Cancer Inst. 2019 Jun 19. pii: 5520439. doi: 10.1093.
    PubMed     Text format    


  4. GUI Y, Liu X, Chen X, Yang X, et al
    A network meta-analysis of surgical treatment in patients with early breast cancer.
    J Natl Cancer Inst. 2019 Jun 11. pii: 5514059. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. DI COSIMO S, Torri V, Porcu L
    RE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
    J Natl Cancer Inst. 2019 Jun 11. pii: 5514057. doi: 10.1093.
    PubMed     Text format    


  6. CHOUDHURY PP, Wilcox AN, Brook MN, Zhang Y, et al
    Comparative validation of breast cancer risk prediction models and projections for future risk stratification.
    J Natl Cancer Inst. 2019 Jun 4. pii: 5511406. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2019
  7. YANG Y, Wu L, Shu XO, Cai Q, et al
    Genetically predicted levels of DNA methylation biomarkers and breast cancer risk: data from 228,951 women of European descent.
    J Natl Cancer Inst. 2019 May 29. pii: 5505447. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. SU Y, Huang J, Wang S, Unger JM, et al
    The Effects of Ganglioside-Monosialic Acid in Taxane-induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.
    J Natl Cancer Inst. 2019 May 15. pii: 5489913. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. GOMEZ SL, Yao S, Kushi LH, Kurian AW, et al
    Is breast cancer in Asian and Asian American women a different disease?
    J Natl Cancer Inst. 2019 May 15. pii: 5489912. doi: 10.1093.
    PubMed     Text format    


  10. LIN CH, Yap YS, Lee KH, Im SA, et al
    Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians versus the US Population.
    J Natl Cancer Inst. 2019 May 15. pii: 5489914. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. TESSIER L, Furzer J, Hodgson D, Cotton C, et al
    Cost-Utility of Early Breast Cancer Surveillance in Survivors of Thoracic Radiation-Treated Adolescent Hodgkin's Lymphoma.
    J Natl Cancer Inst. 2019 May 9. pii: 5485250. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2019
  12. PRAT A, Pascual T, De Angelis C, Gutierrez C, et al
    HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade.
    J Natl Cancer Inst. 2019 Apr 30. pii: 5475264. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. MARIOTTO A, Jayasekerea J, Petkov V, Schechter CB, et al
    Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
    J Natl Cancer Inst. 2019 Apr 24. pii: 5475265. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. MUKHOPADHYAY UK, Oturkar CC, Adams C, Wickramasekera N, et al
    TP53 Status as a Determinant of Pro- versus Anti-tumorigenic Effects of Estrogen Receptor-beta in Breast Cancer.
    J Natl Cancer Inst. 2019 Apr 16. pii: 5452444. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. BADVE S, Gokmen-Polar Y
    TP53 Status and Estrogen Receptor-beta in Triple Negative Breast Cancer: Company matters.
    J Natl Cancer Inst. 2019 Apr 16. pii: 5452445. doi: 10.1093.
    PubMed     Text format    


  16. XU Z, Sandler DP, Taylor JA
    Blood DNA methylation and breast cancer: A prospective case-cohort analysis in the Sister Study.
    J Natl Cancer Inst. 2019 Apr 15. pii: 5466458. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. LI N, McInerny S, Zethoven M, Cheasley D, et al
    Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.
    J Natl Cancer Inst. 2019 Apr 5. pii: 5428180. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2019
  18. KIM RS, Song N, Gavin PG, Salgado R, et al
    Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.
    J Natl Cancer Inst. 2019 Mar 19. pii: 5393262. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. RODRIGUEZ-RUIZ A, Lang K, Gubern-Merida A, Broeders M, et al
    Stand-Alone Artificial Intelligence for Breast Cancer Detection in Mammography: Comparison With 101 Radiologists.
    J Natl Cancer Inst. 2019 Mar 5. pii: 5307077. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2019
  20. KRESOVICH JK, Xu Z, O'Brien KM, Weinberg CR, et al
    Methylation-based biological age and breast cancer risk.
    J Natl Cancer Inst. 2019 Feb 22. pii: 5341521. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. NGUYEN B, Veys I, Leduc S, Bareche Y, et al
    Genomic, transcriptomic, epigenetic, and immune profiling of mucinous breast cancer.
    J Natl Cancer Inst. 2019 Feb 21. pii: 5355042. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. COHN BA, Cirillo PM, Terry MB
    DDT and Breast Cancer: Prospective Study of Induction Time and Susceptibility Windows.
    J Natl Cancer Inst. 2019 Feb 13. pii: 5299924. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. LEE CI, Elmore JG
    Artificial Intelligence for Breast Cancer Imaging: The New Frontier?
    J Natl Cancer Inst. 2019 Feb 5. pii: 5307046. doi: 10.1093.
    PubMed     Text format    


    January 2019
  24. ABDEL-QADIR H, Thavendiranathan P, Austin PC, Lee DS, et al
    The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study.
    J Natl Cancer Inst. 2019 Jan 31. pii: 5304781. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. LENIHAN DJ
    Cardiac Disease After Breast Cancer Treatment: Make Sure to Check Our Blind Spot!
    J Natl Cancer Inst. 2019 Jan 31. pii: 5304780. doi: 10.1093.
    PubMed     Text format    


  26. KRAMER I, Schaapveld M, Oldenburg HSA, Sonke GS, et al
    The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype.
    J Natl Cancer Inst. 2019 Jan 30. pii: 5304371. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. CHEUNG KJ, Davidson NE
    Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era.
    J Natl Cancer Inst. 2019 Jan 28. pii: 5303805. doi: 10.1093.
    PubMed     Text format    


  28. PAREJA F, Lee JY, Brown DN, Piscuoglio S, et al
    The Genomic Landscape of Mucinous Breast Cancer.
    J Natl Cancer Inst. 2019 Jan 11. pii: 5288408. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. REEVES KW, Santana MD, Manson JE, Hankinson SE, et al
    Urinary Phthalate Biomarker Concentrations and Postmenopausal Breast Cancer Risk.
    J Natl Cancer Inst. 2019 Jan 10. pii: 5284913. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. HUILLARD O, Le Strat Y, Dubertret C, Goldwasser F, et al
    RE: Associations between breast cancer survivorship and adverse mental health outcomes: a systematic review.
    J Natl Cancer Inst. 2019 Jan 10. pii: 5284914. doi: 10.1093.
    PubMed     Text format    


  31. SPRAGUE BL, Kerlikowske K, Bowles EJA, Rauscher GH, et al
    Trends in Clinical Breast Density Assessment From the Breast Cancer Surveillance Consortium.
    J Natl Cancer Inst. 2019 Jan 8. pii: 5280767. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2018
  32. TERRY MB, Daly MB, Phillips KA, Ma X, et al
    Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk.
    J Natl Cancer Inst. 2018 Nov 28. pii: 5212812. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. HATEM E, Azzi S, El Banna N, He T, et al
    Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2018 Nov 20. pii: 5193772. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. HATEM E, Azzi S, El Banna N, He T, et al
    Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2018 Nov 20. pii: 5342932. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. KENSLER KH, Poole EM, Heng YJ, Collins LC, et al
    Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.
    J Natl Cancer Inst. 2018 Nov 15. pii: 5184399. doi: 10.1093.
    PubMed     Text format     Abstract available


  36. CARREIRA H, Williams R, Muller M, Harewood R, et al
    Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review.
    J Natl Cancer Inst. 2018 Nov 7. pii: 5164282. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2018
  37. QIAN F, Wang S, Mitchell J, McGuffog L, et al
    Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.
    J Natl Cancer Inst. 2018 Oct 12. pii: 5128773. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. TRAPP E, Janni W, Schindlbeck C, Juckstock J, et al
    Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127124. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. SPARANO JA, Henry NL
    Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127122. doi: 10.1093.
    PubMed     Text format    


  40. DESANTIS CE, Jemal A
    Re: Black-White Breast Cancer Incidence Trends: Effects of Ethnicity.
    J Natl Cancer Inst. 2018 Oct 10. pii: 5126439. doi: 10.1093.
    PubMed     Text format    


    September 2018
  41. LEE JY, Joo HS, Choi HJ, Jin S, et al
    Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.
    J Natl Cancer Inst. 2018 Sep 27. pii: 5103386. doi: 10.1093.
    PubMed     Text format     Abstract available


  42. HELZLSOUER KJ
    Can Less Be More for Individuals With Low-Risk Breast Cancer?
    J Natl Cancer Inst. 2018 Sep 18. pii: 5101448. doi: 10.1093.
    PubMed     Text format    


  43. JAYASEKERA J, Schechter CB, Sparano JA, Jagsi R, et al
    Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.
    J Natl Cancer Inst. 2018 Sep 18. pii: 5101449. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2018
  44. MARINOVICH ML, Hunter KE, Macaskill P, Houssami N, et al
    Breast Cancer Screening Using Tomosynthesis or Mammography: A Meta-analysis of Cancer Detection and Recall.
    J Natl Cancer Inst. 2018 Aug 9. pii: 5068658. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. SHIMELIS H, LaDuca H, Hu C, Hart SN, et al
    Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
    J Natl Cancer Inst. 2018 Aug 7. pii: 5062996. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2018
  46. DIERAS V, Rugo HS, Schnell P, Gelmon K, et al
    Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
    J Natl Cancer Inst. 2018 Jul 18. pii: 5055701. doi: 10.1093.
    PubMed     Text format     Abstract available



  47. Corrigendum to "Cost and Complications of Local Therapies for Early-Stage Breast Cancer".
    J Natl Cancer Inst. 2018 Jul 16. pii: 5054617. doi: 10.1093.
    PubMed     Text format    


  48. LU DL, Le Cornet C, Sookthai D, Johnson TS, et al
    Circulating 27-Hydroxycholesterol and Breast Cancer Risk: Results From the EPIC-Heidelberg Cohort.
    J Natl Cancer Inst. 2018 Jul 16. pii: 5054612. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. DAVIS LYNN BC, Rosenberg PS, Anderson WF, Gierach GL, et al
    Black-White Breast Cancer Incidence Trends: Effects of Ethnicity.
    J Natl Cancer Inst. 2018 Jul 5. pii: 5049141. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  50. LAMBERTINI M, Campbell C, Bines J, Korde LA, et al
    Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.
    J Natl Cancer Inst. 2018 Jun 5. pii: 5033460. doi: 10.1093.
    PubMed     Text format     Abstract available


  51. CATHCART-RAKE E, Gast KC, Ruddy KJ
    What Can We Learn From Menstrual Patterns After Treatment for HER2-Positive Breast Cancer?
    J Natl Cancer Inst. 2018 Jun 5. pii: 5033462. doi: 10.1093.
    PubMed     Text format    



  52. Corrigendum to "Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer".
    J Natl Cancer Inst. 2018;110:684.
    PubMed     Text format    


    May 2018
  53. PATTERSON RE, Marinac CR, Sears DD, Kerr J, et al
    The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes.
    J Natl Cancer Inst. 2018 May 18. pii: 4999668. doi: 10.1093.
    PubMed     Text format     Abstract available


  54. LOHMANN AE, Pimentel I, Goodwin PJ
    Novel Insights Into the Impact of Lifestyle-Based Weight Loss and Metformin on Obesity-Associated Biomarkers in Breast Cancer.
    J Natl Cancer Inst. 2018 May 18. pii: 4999672. doi: 10.1093.
    PubMed     Text format    


    April 2018
  55. DESMEDT C, Demicheli R, Fornili M, Bachir I, et al
    Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.
    J Natl Cancer Inst. 2018 Apr 30. pii: 4975381. doi: 10.1093.
    PubMed     Text format     Abstract available


  56. JAYASEKERA J, Li Y, Schechter CB, Jagsi R, et al
    Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer.
    J Natl Cancer Inst. 2018 Apr 28. pii: 4990602. doi: 10.1093.
    PubMed     Text format     Abstract available


  57. BIDARD FC, Michiels S, Riethdorf S, Mueller V, et al
    Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
    J Natl Cancer Inst. 2018 Apr 12. pii: 4969338. doi: 10.1093.
    PubMed     Text format     Abstract available


  58. CHOI HJ, Joo HS, Won HY, Min KW, et al
    Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  59. VERMA V, Simone CB 2nd, Mishra MV
    Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    March 2018
  60. MATIKAS A, Foukakis T, Bergh J
    RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Mar 29. pii: 4956469. doi: 10.1093.
    PubMed     Text format    


  61. HAWK E, Maresso KC, Brown P
    NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question.
    J Natl Cancer Inst. 2018 Mar 15. pii: 4938606. doi: 10.1093.
    PubMed     Text format    


  62. RITZWOLLER DP, Hassett MJ, Uno H, Cronin AM, et al
    Development, Validation, and Dissemination of a Breast Cancer Recurrence Detection and Timing Informatics Algorithm.
    J Natl Cancer Inst. 2018;110:273-281.
    PubMed     Text format     Abstract available


    February 2018
  63. GAIL MH, Pfeiffer RM
    Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening.
    J Natl Cancer Inst. 2018 Feb 27. pii: 4912416. doi: 10.1093.
    PubMed     Text format     Abstract available


  64. ZACHARIAE R, Amidi A, Damholdt MF, Clausen CDR, et al
    Internet-Delivered Cognitive-Behavioral Therapy for Insomnia in Breast Cancer Survivors: A Randomized Controlled Trial.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881759. doi: 10.1093.
    PubMed     Text format     Abstract available


  65. OESTERREICH S, Lucas PC, McAuliffe PF, Bruno TC, et al
    Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881762. doi: 10.1093.
    PubMed     Text format    


  66. DESMEDT C, Salgado R, Fornili M, Pruneri G, et al
    Immune Infiltration in Invasive Lobular Breast Cancer.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881757. doi: 10.1093.
    PubMed     Text format     Abstract available


  67. IRWIN MR
    Innovation in the Treatment of Insomnia in Breast Cancer Survivors.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881761. doi: 10.1093.
    PubMed     Text format    


  68. BROWN J, Rathbone E, Hinsley S, Gregory W, et al
    Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
    J Natl Cancer Inst. 2018 Feb 7. pii: 4842040. doi: 10.1093.
    PubMed     Text format     Abstract available


  69. BANDOS H, Melnikow J, Rivera DR, Swain SM, et al
    Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  70. RIVERA DR, Ganz PA, Weyrich MS, Bandos H, et al
    Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  71. JAGSI R, Momoh AO, Qi J, Hamill JB, et al
    Impact of Radiotherapy on Complications and Patient-Reported Outcomes After Breast Reconstruction.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    January 2018
  72. LINDSTROM LS, Yau C, Czene K, Thompson CK, et al
    Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
    J Natl Cancer Inst. 2018 Jan 19. pii: 4780395. doi: 10.1093.
    PubMed     Text format     Abstract available


  73. OZTURK TOPCU T, Jerzak KJ, Warner E
    RE: Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2018 Jan 10. pii: 4797407. doi: 10.1093.
    PubMed     Text format    


  74. LASKY-SU JA, Zeleznik OA, Eliassen AH
    Using Metabolomics to Explore the Role of Postmenopausal Adiposity in Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795354. doi: 10.1093.
    PubMed     Text format    


  75. MOORE SC, Playdon MC, Sampson JN, Hoover RN, et al
    A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795343. doi: 10.1093.
    PubMed     Text format     Abstract available


  76. SCHRIJVER WAME, Suijkerbuijk KPM, van Gils CH, van der Wall E, et al
    Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Jan 5. pii: 4791841. doi: 10.1093.
    PubMed     Text format     Abstract available


  77. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  78. GOLDVASER H, Barnes TA, Seruga B, Cescon DW, et al
    Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  79. JOHNSON SB, Park HS, Gross CP, Yu JB, et al
    Use of Alternative Medicine for Cancer and Its Impact on Survival.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    December 2017
  80. POORVU PD, Winer EP
    Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718502. doi: 10.1093.
    PubMed     Text format    


  81. KURIAN AW, Bondarenko I, Jagsi R, Friese CR, et al
    Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718501. doi: 10.1093.
    PubMed     Text format     Abstract available


  82. GLUZ O, Nitz U, Liedtke C, Christgen M, et al
    Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
    J Natl Cancer Inst. 2017 Dec 8. pii: 4698155. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  83. BELKACEMI Y, Kuten A
    RE: Regional Nodal Irradiation After Breast-Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    J Natl Cancer Inst. 2017 Nov 21. pii: 4645256. doi: 10.1093.
    PubMed     Text format    


  84. MEIER M, Orr N
    Genetic Determinants of Breast Cancer Risk in Childhood Cancer Survivors.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  85. MORTON LM, Sampson JN, Armstrong GT, Chen TH, et al
    Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  86. DESHMUKH AA, Shirvani SM, Lal L, Swint JM, et al
    Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  87. SCHWARZ LJ, Hutchinson KE, Rexer BN, Estrada MV, et al
    An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    October 2017
  88. LAMBERTINI M, Kroman N, Ameye L, Cordoba O, et al
    Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2017 Oct 26. doi: 10.1093.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: